Safety considerations of recombinant protein therapy: introductory comments.
Hayes
T J
TJ
Hoffmann-La Roche Inc., Nutley, New Jersey 07110-1199, USA.
Ryffel
B
B
D000818:Animals; D000917:Antibody Formation; D006801:Humans; D007377:Interleukin-3 / Q000276:immunology; D011994:Recombinant Proteins / Q000592:standards* / Q000627:therapeutic use*
D007377:Interleukin-3; D011994:Recombinant Proteins